Heather A. Wakelee

Cancer Prevention Institute of California

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index88

i10-index295

Publications956

Citations33,952

Grants

1 total · 0 active

NIH #5M01RR000070-46

CLINICAL TRIAL: ENZASTAURIN AND EROLTINIB IN TUMORS AND NON-SMALL CELL LUNG CANC

Amount: $1K
Period: 2007-12-01 → 2008-05-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at STANFORD UNIVERSITY

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 122

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
Cancer Discovery · 2026-06-22
Outcomes of atypical EGFR mutations in early-stage EGFR -mutated non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology · 2026-05-28
Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study
British Journal of Cancer · 2026-04-27
Corrigendum to ‘MA04.04 Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study’ [Journal of Thoracic Oncology Volume 20 Issue 10 Supplement 1 (2025) S67]
Journal of Thoracic Oncology · 2026-04-01
Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non–Small Cell Lung Cancer
JCO Precision Oncology · 2026-04-01 · 1 citations
Corrigendum to ‘Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes’ [JTO Clinical and Research Reports 6 (2025) 100914]
JTO Clinical and Research Reports · 2026-03-20
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials
Lung Cancer · 2026-02-07
Corrigendum to “KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status” [Cancer Treatment and Research Communications 47 (2026) 101227]
Cancer Treatment and Research Communications · 2026-01-01
KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status
Cancer Treatment and Research Communications · 2026-01-01
Eligibility and Prognostic Performance of Smoking Duration–Based Versus Pack-Year–Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups
Annals of Internal Medicine · 2025-12-15 · 1 citations
Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Table S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Figure S8 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Table S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Table S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Table S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Table S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11
Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2025-12-11

Open author page on OpenAlex →